 |
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312-773X (Online)
Issue: Volume 15, book 1, 2009
Subject Collection: Medicine
Page: 49 - 52
DOI: 10.5272/jimab.1512009_49
Online date:Aug 5, 2009
OUR EXPERIENCE WITH IRINOTECAN AND BOLUS FLUOROURACIL
/ LEUCOVORIN IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
Deyan Davidov
Department of Chemotherapy, Oncological Center, Medical University,
Pleven, Bulgaria
SUMMARY: Background: Irinotecan
is a topoisomerase I inhibitor that prolongs survival as first- line therapy
in patients with advanced or metastatic colorectal cancer Aim: The aim of this study was to evaluate the efficacy and toxicity
of Irinotecan combined with bolus Fluorouracil and Leucovorin. Methods: In the period 2006- 2008 38 consecutive patients with metastatic
colorectal cancer entered the study. The treatment schedule consists of
Irinotecan 180 mg/m2 i.v. day 1, Fluorouracil i.v. bolus 450 mg/m2 days
2- 5 and Leucovorin i.v. bolus 35 mg/m2 day 2- 5 with repetition every
21 days. Results: Overall response rate was 34,2% with
two complete remissions. Median survival was 15,4 months. Diarrhea, nausea,
vomiting and mucositis were most common side effects. Conclusions: The combination of Irinotecan with bolus Fluorouracil / Leucovorin as
first- line therapy for patients with metastatic colorectal cancer offer
consistently improved tumour control and prolonged survival.
Key words: Metastatic colorectal cancer, First- line
reatment, Irinotecan, Response rate.
Page: 49-52; FULL TEXT PDF (121 KB)